G
Gaudi Clinical
Regenerative medicine support services for healthcare institutions.
About Gaudi Clinical
Gaudi Clinical is a Tokyo-based biotech startup spin-off from Juntendo University, dedicated to democratizing access to regenerative medicine. The company operates as a specialized Contract Development and Manufacturing Organization (CDMO), providing decentralized "Kiosk-type" Cell Processing Centers (CPCs) directly to medical clinics. This innovative infrastructure allows healthcare providers to process adipose-derived stem cells (ASCs) and PRP on-site, significantly reducing logistical costs and ensuring high-quality, safe treatments for orthopedic and dental conditions.
Beyond hardware, Gaudi Clinical offers a comprehensive digital platform that manages the entire cell manufacturing lifecycle, from patient data to quality control. By integrating IoT and cloud technology, the company ensures strict compliance with regenerative medicine laws while collecting valuable Real World Data (RWD) to further clinical research. Their solution bridges the gap between advanced academic research and practical clinical application, creating a seamless ecosystem for next-generation therapies.
The company has established strategic alliances with major industry players like Sysmex and secured funding from top-tier investors including JIC Venture Growth Investments and JAFCO. Gaudi Clinical aims to become the standard infrastructure for cell therapy in Japan and globally, promoting a future where advanced regenerative treatments are accessible, affordable, and data-driven.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Healthcare Services, Biotechnology, Spinout, Sustainable Development Goals, Biotech and Pharma, DT and LS, science-based
- Technology
- Hardware
- Business model
- Manufacturing, SaaS
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Feb 2025 | $10M | $42M | JAFCO · Mizuho Capital · Mitsui Sumitomo Insurance Venture Capital · Mirai Sozo Capital | ↗ |
| SEEDOther financing | Nov 2022 | $2.3M | $9.2M | Undisclosed | — |
Growth signals
Latest recorded traffic for Gaudi Clinical is 3.5K monthly website visits, up 29.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Gaudi Clinical in the Tokyo ecosystem
The Gaudi Clinical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
JIC Venture Growth Investments
JAFCO
Mizuho Capital
Mitsui Sumitomo Insurance Venture Capital- MCMirai Sozo Capital
Samurai Incubate
KISCO- SCShizuoka Capital
Other known investors1 additional known investor
Juntendo University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gaudi Clinical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gaudi Clinical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










